Please login to the form below

Not currently logged in
Email:
Password:

Lilly partner with Alizé Pharma on diabetes

Alizé has entered into a research collaboration and license option agreement with Lilly over the development of a type 2 diabetes treatment

Alizé Pharma has entered into a collaboration and license option agreement with Eli Lilly & Co over a development programme for agonists to be used in the treatment of type 2 diabetes.

Under the terms of the deal, Lilly will pay an undisclosed upfront fee and both companies will collaborate on Alizé's AZP-01 project. As a result, Lilly will be granted an exclusive option to license the programme in accordance with predefined terms.

Alizé Pharma president and founder, Thierry Abribat said: "We are very pleased with this first agreement with Lilly, a recognised leader in the field of diabetes."

"This collaboration will put our UAG programme on the best possible track. It gives us access to Lilly's proven expertise in developing first-in-class molecules, while leveraging our resources and remaining totally in line with our business plan," he continued.

The AZP-01 programme aims at developing unacylated ghrelin (UAG) agonists, a new potential therapeutic class for the treatment of type 2 diabetes.

Philip J Larsen, chief scientific officer for diabetes research at Lilly said: "As part of our commitment to remain leaders in diabetes care, we look forward to launching this research collaboration with Alizé on this promising new target, and working together to validate the therapeutic potential of drugs in this class."

The Alizé Pharma Group, based in France, is made up of privately-held biopharmaceutical companies who specialise in the development of innovative therapeutics for the treatment of metabolic diseases and cancer. The group handles preclinical and clinical development and establishes partnerships with the pharmaceutical industry via codevelopment or out-licensing agreements.

25th January 2010

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

The immunotherapy knowledge gap: keeping the patient at the heart of cancer treatment
Advances in cancer treatment are frequent, but how much do we actually understand about these new treatments?...
Value is in the eye of the customer. Co-creation is a bridge to value.
We conducted 16 hours of qualitative interviews with HCPs and Senior Pharma industry leaders in the UK, supported with in-depth industry scanning. Our interviews reveal important insights about the tensions...
Partnering with Patients and Caregivers in Clinical Research
...